RonaldGNahassMDMHCM,FIDSA

PubMed

• Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses.
  Man-Fung Yuen, Scott Fung, Xiaoli Ma, Tuan T Nguyen, Tarek Hassanein, Hie-Won Hann, Magdy Elkhashab, Ronald G Nahass, James S Park, Ira M Jacobson, Walid S Ayoub, Stev...> ;JHEP Reports. 2024 Apr 1
• The Association of Serotonin Toxicity with Combination Linezolid-Serotonergic Agent Therapy: A Systematic Review and Meta-Analysis.
  Savanna SanFilippo, Jacques Turgeon, Veronique Michaud, Ronald G Nahass, Luigi Brunetti> ;Pharmacy. 2023 Nov 20
• 1 citations
  Successful Treatment ofProsthetic Joint Infection With Single-Stage Exchange and Oral Antibiotics.
  Kevin Kohm, Kathleen Seneca, Krystle Smith, Danielle Heinemann, Ronald G Nahass> ;Open Forum Infectious Diseases. 2023 Aug 1
• 1 citations
  Relationship between Body Composition and Serum Immunoglobulin Concentrations after Administration of Intravenous Immune Globulin-Preclinical and Clinical Evidence.
  Luigi Brunetti, Helene Chapy, Ronald G Nahass, Rebecca Moore, Andrew Wassef, Derek Adler, Edward Yurkow, Leonid Kagan> ;Pharmaceutics. 2023 Feb 3
• 9 citations
  Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
  Harry L A Janssen, Jinlin Hou, Tarik Asselah, Henry L Y Chan, Fabien Zoulim, Yasuhito Tanaka, Ewa Janczewska, Ronald G Nahass, Stefan Bourgeois, Maria Buti, Pietro Lam...> ;Gut. 2023 Jul 1
• 1 citations
  Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection.
  Olav Dalgard, Alain H Litwin, Oren Shibolet, Jason Grebely, Ronald Nahass, Frederick L Altice, Brian Conway, Edward J Gane, Anne F Luetkemeyer, Cheng-Yuan Peng, David ...> ;Journal of Addictive Diseases. 2022 Aug 3
• 16 citations
  Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
  Mark S Sulkowski, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff, Hie-Won L Hann, Douglas T Dieterich, Ronald G Nahass, James S Park, Sing Chan, Steven-Huy B ...> ;Journal of Hepatology. 2022 Nov 1
• 12 citations
  Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
  Man-Fung Yuen, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff, Hie-Won L Hann, Douglas T Dieterich, Ronald G Nahass, James S Park, Sing Chan, Steven-Huy B Han...> ;Journal of Hepatology. 2022 Sep 1
• 5 citations
  Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis.
  Savanna San Filippo, Brynna Crovetto, John Bucek, Ronald G Nahass, Marc Milano, Luigi Brunetti> ;Open Forum Infectious Diseases. 2022 Apr 1
• 48 citations
  Risk Factors and Outcomes of Hospitalized Patients With Severe Coronavirus Disease 2019 (COVID-19) and Secondary Bloodstream Infections: A Multicenter Case-Control Study.
  Pinki J. Bhatt, Stephanie Shiau, Luigi Brunetti, Yingda Xie, Kinjal Solanki, Shaza Khalid, Sana Mohayya, Pak Ho Au, Christopher Pham, Priyanka Uprety, Ronald Nahass, N...> ;Clinical Infectious Diseases. 2021 Jun 15
• 42 citations
  Impact of tocilizumab administration on mortality in severe COVID-19
  Andrew Tsai, Oumou Diawara, Ronald Nahass, Luigi Brunetti> ;Scientific Reports. 2020 Nov 5
• 5 citations
  Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis.
  Thomas S Hong, Jimmy Gonzalez, Ronald Nahass, Luigi Brunetti> ;Pharmacy. 2020 Nov 5
• 46 citations
  Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19.
  Luigi Brunetti, Oumou Diawara, Andrew Tsai, Bonnie L. Firestein, Ronald Nahass, George J. Poiani, Naomi Schlesinger> ;Journal of Clinical Medicine. 2020 Sep 14
• 887 citations
  Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
  Jason D Goldman, David C. Lye, David S.C. Hui, Kristen M. Marks, Raffaele Bruno, Rocio Montejano, Christoph D. Spinner, Massimo Galli, Mi Young Ahn, Ronald Nahass, Yao...> ;The New England Journal of Medicine. 2020 May 27
• 11 citations
  Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis
  Palna Mehta, Ronald Nahass, Luigi Brunetti> ;Clinical Infectious Diseases. 2020 May 9
• 30 citations
  Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disopr...
  Joseph J. Eron, Chloe Orkin, Douglas Cunningham, Federico Pulido, Frank A. Post, Stéphane De Wit, Erkki Lathouwers, Veerle Hufkens, John Jezorwski, Romana Petrovic, Ki...> ;Antiviral Research. 2019 Oct 1
• Burkitt lymphoma presenting with fever of unknown origin and isolated hypoglossal nerve palsy.
  Kathleen Seneca, Ronald Nahass, Rachel H. Adler> ;Journal of the American Association of Nurse Practitioners. 2020 May 1
• 2 citations
  How Do You Measure Up: Quality Measurement for Improving Patient Care and Establishing the Value of Infectious Diseases Specialists.
  Joshua C. Eby, Michael A. Lane, Michael A. Horberg, Clare N. Gentry, Susan E. Coffin, Amy J. Ray, Kathleen R Sheridan, Dale W. Bratzler, David Wheeler, Molade Sarumi, ...> ;Clinical Infectious Diseases. 2019 May 17
• 2 citations
  Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older.
  Cheng Yuan Peng, Oren Shibolet, Ronald Nahass, Peggy Hwang, Eliav Barr, Michael N. Robertson, Barbara Haber> ;Gerontology & Geriatric Medicine. 2019 Jan 22
• 4 citations
  The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone.
  Luigi Brunetti, Seung Mi Lee, Ronald Nahass, David Suh, Benjamin Miao, John Bucek, Dong-Won Kim, Ok Kyu Kim, Dong-Churl Suh> ;International Journal of Infectious Diseases. 2019 Jan 1
• 439 citations
  Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
  Raymond T. Chung, Marc G. Ghany, Arthur Y. Kim, Kristen M. Marks, Susanna Naggie, Hugo E. Vargas, Andrew Aronsohn, Debika Bhattacharya, Tina Broder, Oluwaseun Falade-N...> ;Clinical Infectious Diseases. 2018 Oct 30
• 31 citations
  Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
  Benjamin Y. Winer, Elham Shirvani-Dastgerdi, Yaron Bram, Julie Sellau, Benjamin E. Low, Heath E. Johnson, Tiffany Huang, Gabriela Hrebikova, Brigitte Heller, Yael Shar...> ;Science Translational Medicine. 2018 Jun 27
• 72 citations
  Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat,...
  Chloe Orkin, Jean-Michel Molina, Eugenia Negredo, Jose R. Arribas, Joseph Gathe, Joseph J. Eron, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Romana Petrovic, ...> ;The Lancet. HIV. 2018 Jan 1
• 20 citations
  Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.
  David L. Wyles, Heiner Wedemeyer, Ziv Ben-Ari, Edward Gane, Jesper Bach Hansen, Ira M. Jacobson, Alex Lund Laursen, Annie Luetkemeyer, Ronald Nahass, Stephen Pianko, S...> ;Hepatology. 2017 Dec 1
• 14 citations
  Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment‐naïve, noncirrhotic HCV genotype 3‐infected patients
  Edward Gane, Ronald Nahass, Velimir Luketic, Ernest Asante-Appiah, Peggy Hwang, Michael N. Robertson, Janice Wahl, Eliav Barr, Barbara Haber> ;Journal of Viral Hepatitis. 2017 Oct 1
• Join now to see all

Journal Articles

• Thorn-Induced Alternaria septic arthritis and osteomyelitis of the hand  
  Li Boning, Boretz R, Nahass RG, Infect Dis Clin Practice, 1/1/2016
• Linkage to Care for Hepatitis C Virus (HCV) Among Suburban Heroin Users in New Jersey  
  Akyar E, Seneca KH, Akyar S, Schoefield N, Schwartz MP, Nahass RG, Emerg Infect Dis, 1/1/2016
• Implications of baseline HCVRNA level and intrapatient viral load variability on OBV/PTV/R + DSV 12-week treatment outcomes  
  Brown RS, Puoti M, Cooper C, Wyles DL, Sepe TE, Nahass RG, et al, Journal of Hepatology, 1/1/2015
• The infectious diseases physician in the future of healthcare;not only about antibiotic prescribing  
  Nahass RG, CID, 1/1/2015
• The next frontier in hospital/physician co-management  
  Nahass RG, Phys Leadership J, 1/1/2015
• PegInterferon/Ribavirin for 12 weeks vs Sofosbuvir + Ribavirin for 16 or 24 weeks in Genotype 3 HCV infected patients and treatment-experienced cirrhotic pacientes wit...  
  Foster GR, Pianko C, Cooper,A Brown A,Forton D, Nahass RG, Sofosbuvir, Hepatology, 1/1/2015
• Infectious diseases manpower; a looming crisis  
  Nahass RG, Infect Dis Clin Practice, 1/1/2015
• Clinical and economic impact of empiric extended infusion piperacillin-tazobactam in a community medical center  
  Brunetti L, Poustchi S, Cunningham D. Toscani M, Nguyen J, Lim J, Ding Y, Vigdor S, Nahass RG, Ann Pharmacotherapy Annals of Pharmacotherapy, 1/1/2015
• Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 and Treatment-Experienced Cirrhotic Patients with HCV Genotype 2  
  Massetto B,Nahass RG, et al, Gastro, 1/1/2015
• Sofosbuvir with velpatasvir in treatment-naive non-cirrhotic patients with genotype 1-6 hepatitis C virus infection: a randomized trial  
  Everson GT, Towner WJ, David MN, Wyles D, Nahass RG, et al, Annals Int Med, 1/1/2015
• Cefoxitin plasma and subcutaneous adipose tissue concentration in patients undergoing sleeve gastrectomy  
  Nahass RG, Clinical Therapeutics, 1/1/2015
• Ledispavir plus GS-9451 and PegIFN/RBV with high SVR12 rates in genotype 1 hepatitis C infecton  
  Marcellin P, Manns MP, Janczewska E, Muir AJ, Wu X, Trenkle D, Pang P, Kanawar B, Dvory-Sobol H, Subramanian M, McHutchison J, Nahass RG, Gordon SC, Jacobson IM, NEJM, 1/1/2014
• Do clinical trials fit in private practice?  
  Nahass RG, Open Forum Infect Dis, 1/1/2014
• Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir(MK-8742) with or without ribavirin in patients with hepatitis C vir...  
  Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, et al, Lancet, 1/1/2014
• Infectious disease specialty intervention is associated with decreased mortality and lower healthcare costs  
  Schmitt S, McQuillen D, Nahass RG, et al, Clin Infect Dis, 1/1/2013
• Hepatitis C screening: Summary of recommendations from the clinical decision tool  
  Boldt MD, Brill JV, Davis GL, Gordon SC, Kim AY, Kosinski LR, Levy AG, Nahass RG, Allen JI, Gastroenterology, 1/1/2012
• Electronic health record technology  
  Nahass TA, Nahass RG, JAMA, 1/1/2012
• Using active microbiologic surveillance and enhanced infection control measures to control an outbreak of health care-associated extended-spectrum beta-lactamase-produ...  
  Langer AJ, Lafaro P, Genese CA, McDonough P, Nahass R, Robertson C, Am J Inf C, 1/1/2009
• The value of infectious diseases specialists: non – patient care activities  
  McQuillen DP, Petrak RM, Wasserman RB, Nahass RG, et al, CID, 1/1/2008
• Evaluation of Subcutaneous Proleukin (Interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and Gender Differences in the Baseline  
  S.L. Pett A1, H. Wand A1, M.G. Law A1,et al and the Community Programs for Clinical Research in AIDS (Nahass RG, member), HIV Clinical Trials, 1/1/2006
• HIV – 1 reverse transcriptase mutations found in a drug-experienced patient confer reduced susceptibility to multiple nucleoside reverse transcriptase inhibitors  
  Fitzgibbon JE, Dicola MB, Kiri S, Sha B, Pottage J, Nahass R, et al, Antiviral Therapy, 1/1/2001
• Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections  
  Cheung T , Jayaweera D, Pearce, P Benson, Nahass R, Nusrat R, et al, Int J STD AIDS, 1/1/2000
• A randomized trial of daily and thrice-weekly trimethoprim- Sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infec...  
  El-Sadr WM, Luskin-Hawk R, McCabe Yurik T, Walker J, et al and the Community Programs for Clinical Research in AIDS (Nahass RG, member), Clin Infect Dis, 1/1/1999
• The Lyme disease controversy: Letter to the Editor  
  Nahass RG, Herman DJ, Hirsh EJ, Arch Intern Med, 1/1/1997
• Vertebral osteomyelitis due to roseomonas: the first case and a review of the evaluation of vertebral osteomyelitis  
  Nahass RG, Wisneski R, Herman D, Hirsh E, Goldblatt K, Clin Infect Dis, 1/1/1995
• Join now to see all

Abstracts/Posters

• C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)
  Dore GJ, Altice F, Litwin AH, Grebely J, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, et al, EASL, Barcelona, Spain, 1/1/2016
• High efficacy of sofosbuvir/velpatasvir plus gs-9857 for 12 weeks in treatment-experienced genotype 1-6 hcv-infected patients, including those previously treated with ...
  Lawitz E, Kowdley K, Curry M, Reau N, Nguyen M, Kwo P, Jacobson I, Tran T, Nahass RG, EASL, Barcelona, Spain, 1/1/2016
• Sofosbuvir + PEGInterferon/Ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experineced cirrhotic ...
  Foster GR, Pianko S, Cooper C, Brown A, Forton D, Nahass RG, et al, EASL, Vienna, Austria, 1/1/2015
• A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (smv) plus sofosbuvir (sof) in treatment-naïve and -experie...
  Kwo P, Gitlin N, Nahass RG, et al, EASL, Vienna, Austria, 1/1/2015
• Implications of baseline HCV RNA level and intrapatient viral load variability on OBV/PTV/R + DSV 12-Week Treatement Outcomes
  Brown RS, Puoti M, Cooper C, Wyles DL, Sepe TE, Nahass RG, et al, EASL, Vienna, Austria, 1/1/2015
• Efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in the treatment naive, noncirrhotic HCV genotype 3 infected patients
  Gane E, Nahass RG, Luketic V, Hwang P, Robertson M, et al, EASL, Vienna, Austria, 1/1/2015
• Hepatitis C Virus (HCV) In Young Suburban Heroin Users In New Jersey; Part Of The Second Wave Of Hepatitis C
  Nahass RG, et al, ID Week, San Diego, CA, 1/1/2015
• C-EDGE CO-STAR: Adherence and Drug use in HCV-Infected Persons who Inject Drugs (PWID) on Opioid Agonist Therapy (OAT) receiving Grazoprevir + Elbasvir (GZR/EBR) fixed...
  Nahass RG, INHSU, 1/1/2015
• High efficacy of grazoprevir/elbasvir among HCV GT1, GT4, or GT6 infected patients with HIV Co Infection
  Nelson M, Rockstroh J, Mallolas J, Katlama C, Nahass RG, et al, ID Week, San Diego, CA, 1/1/2015
• On treatment viral response of MK-5172/MK-8742 + RBV for 12 weeks in HCV/HIV Co- Infected Patient
  Sulkowski M, Mallolas J, Pol S, Bouliere M, Gerstoft, Shibolet O, Nahass R, et al, Croi, 1/1/2014
• Safety and Efficacy of Treatment with the Interferon-free, Ribavirin-free combination of Sofosbuvir+GS-5816 for 12 Weeks in Treatment Naïve Patients with Genotype 1-6 ...
  Everson GT, Tran TT, Towner WJ, Davis MN, Wyles D, Nahass RG, McNally J, Bainard DM et al, EASL, London, UK, 1/1/2014
• EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY
  Sulkowski M, Mallolas J, Pol S, Bouliere M, Gerstoft, Shibolet O, Nahass R, et al, EASL, London, UK, 1/1/2014
• Switch from NNRTI plus TVD to STB Maintains HIV Suppression and is Well- Tolerated
  Markowitz M, Nahass RG, et al, American Conference for Treatment of HIV, Denver, CO, 1/1/2014
• Innovations in Care to Provide Value in Healthcare Deliver Through Out-Patient Infusion Therapy
  Heinemann D, Nahass RG, Manno A, Association for Vascular Access, National Harbor, MD, 1/1/2014
• Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients, by Baseline Demographics
  Nahass RG, Vierling JM, ID Week, Philadelphia, PA, 1/1/2014
• Daclatasvir in combination with asunaprevir and BMS-791325 for prior null responders with chronic HCV genotype 1 infection
  Gregory Everson G,Sims K,Thuluvath P,Schwartz H,Hassanein T,Lawitz E,Webster L,Bräu N,Desta T,Galati J,Ghalib R,Gitlin N,Han S,Hinestrosa F, Rodriguez-Torres M, Nahass..., 65th Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 1/1/2014
• Efficacy and safety of MK-5172 + MK-8742 ± ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hepatitis C virus genoty...
  Sulkowski MS, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, 65th Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 1/1/2014
• The Greying of an Epidemic: A Descriptive Study of HIV in Patients over 70 Years of Age
  Nahass TA, Pittarelli L, McManus E, Nahass RG, ASM, Denver, CO, 1/1/2013
• A Pseudo-epidemic of Tuberculosis Conversions Using Quantiferon Tb Gold In-tube (qft-git) for Testing High Risk Employees
  Nahass RG, Pittarelli L, Lafaro P, McDonough P, ASM, Denver, CO, 1/1/2013
• High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172/MK-8742 +/- RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study
  Nahass RG, AASLD, Washington, DC, 1/1/2013
• Efficacy and Safety of Sofosbuvir in Patients According to Fibrosis Stage: An Analysis of Phase 3 Data
  K Patel, S Gordon, A Sheikh, Z Younes, J Ma, J McNally, DM Brainard, WT Symonds, JG McHutchison, R Nahass, EM Yoshida, H Reesink, D Nelson, AASLD, Washington, DC, 1/1/2013
• Effectiveness of a pharmacist managed vancomycin dosing protocol in achieving therapeutic levels in a Community Medical Center
  Patel S, Segal R, Brunetti L,Kalabalik J, Nahass RG, IDSA, San Francisco, CA, 1/1/2013
• Demonstrating Value For Antibiotic Stewardship Program (ASP) Through Cost Saving, Improved Antimicrobial Resistance Patterns And Stable Clinical Outcomes In A Communit...
  Nahass RG, Segal R, McDonnough P, Bollwage M, Brunetti L, IDSA, San Francisco, CA, 1/1/2013
• High safety and efficacy of all oral combination regimen, MK 5172/MK 8742 +/- RBV for 12 weeks in HCV infected patients the C Worthy study
  Lawitz E, Vierling J, Murillo A, Kugelmas M, Gerstoft J, Winkle P, Balart L, Christensen P, Ghalib R, Nahass RG, Shaughnessy M, Sun X, Hwang P, Wahl J, Robertson M, H..., 64th Meeting of the Anerican Association for the Study of Liver Diseases, Washington, DC, 1/1/2013
• Efficacy and Safety of Sofosbuvir in Patients According to Fibrosis Stage: An Analysis of Phase 3 Data
  Keyur Patel, Stuart C. Gordon, Aasim M. Sheikh, Ziad Younes, Julie Ma, John McNally, Diana M. Brainard, William T. Symonds, John G. McHutchison, Nahass RG, Eric M. Yos..., 64th Meeting of the Anerican Association for the Study of Liver Diseases, Washington, DC, 1/1/2013
• Join now to see all

Lectures

• Infectious Disease Physicians and the Future of Healthcare 
  1/1/2015
• HIV/HCV Coinfection 
  1/1/2015
• Hepatitits C in Clinical Practice 
  San Diego, CA - 1/1/2015
• Blood Borne Pathogen Risk Reduction 
  1/1/2014
• Infectious Diseases Strategies To Limit Hospitalization, Reduce Risk And Add Value 
  1/1/2014
• Innovations in Infectious Diseases Practice 
  1/1/2014
• Hepatitis C in Clinical Practice 
  Philadelphia, PA - 1/1/2014
• Hepatitis C Update 
  1/1/2014
• Pre Exposure Prophylaxis 
  1/1/2014
• ACO and the ID Clinician 
  1/1/2013
• Hepatitis C Updat 
  1/1/2013
• Hepatitis C and B: An Update 
  1/1/2013
• Accountable Care and the ID Physician 
  1/1/2012
• Payment Reform - Physician Models 
  1/1/2011
• Health Care Reform 
  1/1/2011
• Numerous community presentations on Hepatitis C 
  1/1/2011
• Metabolic Abnormalities of HIV 
  Phoenix, AZ - 1/1/2010
• Perinatal HIV 
  Phoenix, AZ - 1/1/2010
• A Day In the Life 
  Phoenix, AZ - 1/1/2010
• HIV Update 
  1/1/2009
• H1N1 
  1/1/2009
• Blood Borne Pathogen 
  1/1/2009
• Infection Prevention Course 
  1/1/2009
• Herpes Simplex Treatment and Mangement 
  1/1/2009
• Hepatitis C 
  1/1/2009
• Join now to see all